Working… Menu

A Vaccine Study for High Risk Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00944580
Recruitment Status : Withdrawn (unexpectedly low screening results leading to poor accrual)
First Posted : July 23, 2009
Last Update Posted : November 24, 2017
Information provided by (Responsible Party):
Penn State University

Brief Summary:
The purpose of this study is to determine the safety and immunological effects of a vaccine for people diagnosed with high risk neuroblastoma, osteogenic sarcoma, and rhabdomyosarcoma. It is hypothesized that this vaccine could reduce the incidence of relapse.

Condition or disease Intervention/treatment Phase
Neuroblastoma Rhabdomyosarcoma Osteogenic Sarcoma Biological: MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine Phase 1

Detailed Description:

MAGE -A1, MAGE- A3, and NY-ESO-1 are antigens that can be found with significant frequency on neuroblastoma, rhabdomyosarcoma, and osteogenic sarcoma, three relatively common solid tumors that in some cases can be associated with a high risk for relapse. In this study each subject will be screened for the presence of these antigens, and an individualized vaccine will be developed and administered using the subject's own dendritic cells (DC).

This study consists of two phases: a screening phase and a treatment/vaccine phase. First, eligible individuals will be consented into the screening phase. Tumor specimens will be tested by immunohistochemistry or RT-PCR for the presence of MAGE- A1, MAGE- A3, and NY-ESO-1. Those testing positive for one or more antigen can be consented for the treatment phase of the study. Blood will be drawn for DC culture, and approximately one month later a series of three vaccines will be administered at two week intervals. Subjects will receive a topical medication called imiquimod to the vaccine site prior to and following each injection, to help immune cells travel into the area. Study participation occurs over 18 months and also involves periodic physical examinations and blood draws.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study to Determine the Immunologic Effects of a MAGE- A1, MAGE- A3, NY-ESO-1 Vaccine in Patients With High Risk Neuroblastoma, Osteogenic Sarcoma, and Rhabdomyosarcoma
Study Start Date : June 2009
Actual Primary Completion Date : August 2010
Actual Study Completion Date : August 2010

Arm Intervention/treatment
Experimental: Vaccine Intervention
MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine: A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.
Biological: MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine
A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.

Primary Outcome Measures :
  1. The primary objective is to determine if there is an amplification or new development of NY-ESO-1, MAGE-A1, or MAGE-A3 specific CD4+ or CD8+ T cells post-vaccination. [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. The investigators will determine the safety of vaccine and imiquimod administration in these patients. [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Year to 70 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria for Screening Phase:

Patient 1 to 70 years of age with neuroblastoma, rhabdomyosarcoma, or osteogenic sarcoma, who have one or more of the following high risk features:

  • Neuroblastoma:

    • Stage IV disease
    • Stage III disease with n-myc amplification
  • Osteogenic sarcoma:

    • Presence of metastases
    • Elevated alkaline phosphatase or LDH at diagnosis
    • Primary tumor affecting the axial skeleton
    • Poor histopathological response after completion of pre-surgical chemotherapy (≥10% viable tumor)
  • Rhabdomyosarcoma:

    • Stage IV disease
    • Alveolar histology
    • Positive tumor margins, with lymph node positivity

Inclusion Criteria for Vaccine Phase:

  • Patient meets all screening criteria and tumor is positive for NY-ESO-1, MAGE- A1, or MAGE-A3 by immunohistochemistry or RT-PCR.
  • Patients who are between 3 months and 2 years following the completion of therapy, and have achieved at least a very good partial response to primary therapy.
  • No chemotherapy is planned for one month following the last vaccination.
  • Bilirubin <2 mg/dL, and SGOT/SGPT <2.5 x normal
  • Creatinine clearance > 50ml/min as estimated by patient's serum creatinine, weight, and age
  • Room air pulse oximetry >94%
  • Patient is not pregnant
  • Male and female sexually active patients of reproductive who wish to participate must agree to use acceptable contraception
  • Patient is not moribund and has a projected life expectancy >6 months
  • Lansky performance scale > 70, ECOG < 2 (Appendix I)
  • Potential subjects will be tested for HIV 1 and 2 antibodies, HTLV 1/2 antibodies, and for HIV 1, hepatitis C and hepatitis B virus by NAT testing. - -Subjects testing positive for any of these pathogens will be ineligible for vaccine.
  • White blood cells ≥ 2.5 K/µL, Hemoglobin ≥ 8 g/dL, Hematocrit > 25%, and Platelets ≥ 70 K/µL
  • Patient does not have central nervous system involvement.
  • Patient does not a have a history of autoimmune disease, specifically inflammatory bowel disease, systemic lupus erythematosis, or rheumatoid arthritis
  • Patient is not receiving concurrent systemic steroid therapy
  • Patient does not have a known systemic hypersensitivity to imiquimod or any vaccine component

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00944580

Sponsors and Collaborators
Penn State University
Layout table for investigator information
Study Chair: Kenneth G. Lucas, MD Milton S. Hershey Medical Center
Layout table for additonal information
Responsible Party: Penn State University Identifier: NCT00944580    
Other Study ID Numbers: IRB 30761
PSHCI 09-033
First Posted: July 23, 2009    Key Record Dates
Last Update Posted: November 24, 2017
Last Verified: November 2017
Keywords provided by Penn State University:
dendritic cells
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Muscle Tissue
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue